ITM Isotope Technologies Munich has entered into a licensing agreement with Merck KGaA's life science business for the development and commercialization of radiolabeled folate derivatives. These derivatives will be used for therapeutic and diagnostic purposes in the treatment of folate-receptor-positive malignant tumors, such as ovarian cancers. Under the agreement, Merck KGaA will supply ITM with folate precursors for radiolabeling, allowing ITM to advance the clinical development of its folate-receptor-targeting radiopharmaceutical candidates. The license has been expanded to cover all folate-receptor-positive malignant tumors. ITM is currently developing ITM-52, a candidate that combines a folate receptor α-targeting moiety with a medical isotope, and plans to begin phase I clinical testing. The company's theranostic pairing, ITM-55D/ITM-52, aims to overcome existing limitations in screening and treatment.
Thu, 14 Dec 2023 18:10:49 GMT | AuntMinnie Europe